Field Name |
Format |
Description |
PATIENT | Character or Numeric | *Required Code to identify patient (Cohort Patient ID) |
ART_ID | Character See Code ListART_ID Code | Definition | J05A | ART unspecified | J05A-BEV | Beviramat | J05A-PBT | Participant in Blinded Trial | J05AE | PI unspecified | J05AE-MOZ | Mozenavir (DMP-450) | J05AE01 | Saquinavir (gel, not specified) | J05AE01-SQH | Saquinavir hard gel (INVIRASE) | J05AE01-SQS | Saquinavir soft gel (FORTOVASE) | J05AE02 | Indinavir (CRIXIVAN) | J05AE03 | Ritonavir (NORVIR) | J05AE03-H | Ritonavir high dose (NORVIR) | J05AE03-L | Ritonavir low dose (NORVIR) | J05AE04 | Nelfinavir (VIRACEPT) | J05AE05 | Amprenavir (AGENERASE) | J05AR10 | Lopinavir/Ritonavir (Kaletra). Former code: J05AE06 | J05AE07 | Fos-amprenavir (Telzir, Lexiva) | J05AE08 | Atazanavir (Reyataz) | J05AE09 | Tipranavir (Aptivus) | J05AE10 | Darunavir (TMC-114, Prezista) | J05AF | NRTI unspecified | J05AF-ALO | Alovudine | J05AF-AMD | Amdoxovir (DADP) | J05AF-FOZ | Fozivudine tidoxi | J05AF-LDN | Lodenosine (trial drug) | J05AF-RVT | Reverset | J05AF01 | Zidovudine (AZT, RETROVIR) | J05AF02 | Didanosine (ddI) (VIDEX) | J05AF03 | Zalcitabine (ddC) (HIVID) | J05AF04 | Stavudine (d4T) (ZERIT) | J05AF05 | Lamivudine (3TC, EPIVIR) | J05AF06 | Abacavir (1592U89) (ZIAGEN) | J05AF07 | Tenofovir (VIREAD) | J05AF08 | Adefovir (PREVEON) | J05AF09 | Emtricitabine | J05AF10 | Entecavir | J05AF11 | Telbivudine | J05AF13 | tenofovir alafenamide | J05AG | NNRTI unspecified | J05AG-BIC | Bictegravir | J05AG-CPV | Capravirine | J05AG-DPC083 | DPC 083 | J05AG-DPC961 | DPC 961 | J05AG-EMV | Emivirine (MKC442) | J05AG04 | Etravirine (TMC 125). Former code: J05AG-ETV | J05AG-LOV | Loviride | J05AG05 | Rilpivirine (TMC-278). Former code: J05AG-RPV | J05AG01 | Nevirapine (VIRAMUN) | J05AG02 | Delavirdine (U-90152) (RESCRIPTOR) | J05AG03 | Efavirenz (DMP-266) (STOCRIN, SUSTIVA) | J05AG06 | Doravirine | J05AJ01 | raltegravir | J05AJ02 | Elvitegravir (former code: J05AX11) | J05AJ03 | dolutegravir | J05AJ04 | Cabotegravir | J05AR01 | Combivir (Zidovudine/Lamivudine) | J05AR02 | Kivexa (Lamivudine/Abacavir) | J05AR03 | Truvada (Tenofovir/Emtricabine) | J05AR04 | Trizivir (Zidovudine/Lamivudine/Abacavir) | J05AR05 | Douvir-N (Zidovudine/Lamivudine/Nevirapine) | J05AR06 | Atripla (Emtricitabine/Tenofovir/Efavirenz) | J05AR07 | Triomune (Stavudine/Lamivudine/Nevirapine) | J05AR08 | Eviplera/Complera (Emtricitabine/Tenofovir/Rilpivirine) | J05AR09 | Stribild (Emtricitabine/Tenofovir/Elvitegravir/Cobicistat) | J05AR10 | Kaletra/Aluvia (Lopinavir/Ritonavir) | J05AR11 | Lamivudine, tenofovir disoproxil and efavirenz | J05AR12 | Lamivudine and tenofovir disoproxil | J05AR13 | Lamivudine, abacavir and dolutegravir | J05AR14 | Darunavir and cobicistat | J05AR15 | (Evotaz) atazanavir and cobicistat | J05AR16 | lamivudine and raltegravir | J05AR17 | emtricitabine and tenofovir alafenamide | J05AR18 | emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat | J05AR19 | emtricitabine, tenofovir alafenamide and rilpivirine | J05AR20 | emtricitabine, tenofovir alafenamide and bictegravir | J05AR21 | dolutegravir and rilpivirine | J05AR22 | emtricitabine, tenofovir alafenamide, darunavir and cobicistat | J05AR23 | Atazanavir and ritonavir | J05AR24 | lamivudine, tenofovir disoproxil and doravirine | J05AR25 | lamivudine and dolutegravir | J05AR26 | Darunavir and ritonavir | J05AR27 | lamivudine, tenofovir disoproxil and dolutegravir | J05AR30 | Tenofir and emtricitabine | J05AX11 | Elvitegravir (Gilead). (deprecated; replaced by J05AJ02) | J05AX-VIC | Vicriviroc (Schering) | J05AX07 | Enfurvirtide (Fuzeon , T-20) | J05AX08 | Raltegravir (deprecated; replaced by J05AJ01) | J05AX09 | Maraviroc (Pfizer) | J05AX12 | Dolutegravir (deprecated; replaced by J05AJ03) | J05AX29 | fostemsavir | J05AX-CAB | Cabotegravir (GSK-744) (deprecated, replaced by J05AJ04) | L01XX05 | Hydroxyurea/Hydroxycarbamid (Litalir) | V03AX03 | Cobicistat |
| *Required ATC code for the patient's ARV medication Codes are drawn from the Anatomical Therapeutic Chemical (ATC) classification system. The list provided here includes most relevant drugs. A searchable index is available at http://www.whocc.no/atc_ddd_index/ |
ART_SD | YYYY-MM-DD | *Required Date of initiation of treatment |
ART_SD_A | Character < = Before this date D = Exact to the date M = Exact to the month Y = Exact to the year > = After the date U = Unknown
| Date approximation for ART_SD |
ART_ED | YYYY-MM-DD | Date of stopping of treatment |
ART_ED_A | Character < = Before this date D = Exact to the date M = Exact to the month Y = Exact to the year > = After the date U = Unknown
| Date approximation for ART_ED |
ART_RS | Character See Code ListART_RS Code | Definition | 1 | Treatment failure (i.e. virological, immunological, and /or clinical failure) | 1.1 | Virological failure | 1.2 | Partial virological failure | 1.3 | Immunological failure - CD4 drop | 1.4 | Clinical progression | 1.5 | Resistance (based on test result) | 2 | Abnormal fat redistribution | 3 | Concern of cardiovascular disease | 3.1 | Dyslipidaemia | 3.2 | Cardiovascular disease | 4 | Hypersensitivity reaction | 5 | Toxicity, predominantly from abdomen/G-I tract | 5.1 | Toxicity - GI tract | 5.2 | Toxicity - Liver | 5.3 | Toxicity - Pancreas | 6 | Toxicity, predominantly from nervous system | 6.1 | Toxicity - peripheral neuropathy | 6.2 | Toxicity - neuropsychiatric | 6.3 | Toxicity - headache | 7 | Toxicity, predominantly from kidneys | 8 | Toxicity, predominantly from endocrine system | 8.1 | Diabetes | 9 | Haematological toxicity (anemia, etc.) | 10 | Hyperlactataemia/lactic acidosis | 11 | Bone toxicity | 15 | Social contra-indication | 16 | Contra-indication unspecified | 16.8 | Contra-indication expired | 16.9 | Contra-indication - other | 17 | MTCT regimen completed | 70 | Pregnancy - toxicity concerns (during pregnancy) | 75 | Pregnancy - switch to a more appropriate regimen for PMTCT | 88 | Death | 90 | Side effect - any of the above not mentioned | 90.1 | Comorbidity | 91 | Toxicity - other (not mentioned above) | 91.1 | Toxicity - unspecified | 92 | More effective treatment available | 92.1 | Simplified treatment available | 92.2 | Treatment too complex | 92.3 | Drug interaction | 92.31 | Drug interaction - commencing TB/BCG treatment | 92.32 | Drug interaction - ended TB/BCG treatment | 92.33 | Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) | 92.4 | Protocol change | 92.5 | Regular treatment termination (used in tblMED e.g. for DAAs against HCV, antibiotics) | 92.6 | End of empiric therapy | 92.9 | Change in treatment not due to side-effects, failure, poor adherence or contra-indication | 92.91 | Change to a generic drug | 92.92 | Change to branded drug | 93 | Structured Treatment Interruption (STI) | 93.1 | Structured Treatment Interruption (STI)-at high CD4 | 94 | Patient's wish/ decision, not specified above | 94.1 | Non-compliance | 94.2 | Defaulter | 95 | Physician's decision, not specified above | 96 | Pregnancy | 96.1 | Pregnancy intended | 96.2 | Pregnancy ended | 97 | Study treatment | 97.1 | Study treatment commenced | 97.2 | Study treatment completed | 97.6 | Drug not available | 98 | Other causes, not specified above | 99 | Unknown |
| Reason for stopping treatment |
ART_RS2 | Character See Code ListART_RS2 Code | Definition | 1 | Treatment failure (i.e. virological, immunological, and /or clinical failure) | 1.1 | Virological failure | 1.2 | Partial virological failure | 1.3 | Immunological failure - CD4 drop | 1.4 | Clinical progression | 1.5 | Resistance (based on test result) | 2 | Abnormal fat redistribution | 3 | Concern of cardiovascular disease | 3.1 | Dyslipidaemia | 3.2 | Cardiovascular disease | 4 | Hypersensitivity reaction | 5 | Toxicity, predominantly from abdomen/G-I tract | 5.1 | Toxicity - GI tract | 5.2 | Toxicity - Liver | 5.3 | Toxicity - Pancreas | 6 | Toxicity, predominantly from nervous system | 6.1 | Toxicity - peripheral neuropathy | 6.2 | Toxicity - neuropsychiatric | 6.3 | Toxicity - headache | 7 | Toxicity, predominantly from kidneys | 8 | Toxicity, predominantly from endocrine system | 8.1 | Diabetes | 9 | Haematological toxicity (anemia, etc.) | 10 | Hyperlactataemia/lactic acidosis | 11 | Bone toxicity | 15 | Social contra-indication | 16 | Contra-indication unspecified | 16.8 | Contra-indication expired | 16.9 | Contra-indication - other | 17 | MTCT regimen completed | 70 | Pregnancy - toxicity concerns (during pregnancy) | 75 | Pregnancy - switch to a more appropriate regimen for PMTCT | 88 | Death | 90 | Side effect - any of the above not mentioned | 90.1 | Comorbidity | 91 | Toxicity - other (not mentioned above) | 91.1 | Toxicity - unspecified | 92 | More effective treatment available | 92.1 | Simplified treatment available | 92.2 | Treatment too complex | 92.3 | Drug interaction | 92.31 | Drug interaction - commencing TB/BCG treatment | 92.32 | Drug interaction - ended TB/BCG treatment | 92.33 | Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) | 92.4 | Protocol change | 92.5 | Regular treatment termination (used in tblMED e.g. for DAAs against HCV, antibiotics) | 92.6 | End of empiric therapy | 92.9 | Change in treatment not due to side-effects, failure, poor adherence or contra-indication | 92.91 | Change to a generic drug | 92.92 | Change to branded drug | 93 | Structured Treatment Interruption (STI) | 93.1 | Structured Treatment Interruption (STI)-at high CD4 | 94 | Patient's wish/ decision, not specified above | 94.1 | Non-compliance | 94.2 | Defaulter | 95 | Physician's decision, not specified above | 96 | Pregnancy | 96.1 | Pregnancy intended | 96.2 | Pregnancy ended | 97 | Study treatment | 97.1 | Study treatment commenced | 97.2 | Study treatment completed | 97.6 | Drug not available | 98 | Other causes, not specified above | 99 | Unknown |
| Additional reason for stopping treatment Uses same list of codes as ART_RS |
ART_RS3 | Character See Code ListART_RS3 Code | Definition | 1 | Treatment failure (i.e. virological, immunological, and /or clinical failure) | 1.1 | Virological failure | 1.2 | Partial virological failure | 1.3 | Immunological failure - CD4 drop | 1.4 | Clinical progression | 1.5 | Resistance (based on test result) | 2 | Abnormal fat redistribution | 3 | Concern of cardiovascular disease | 3.1 | Dyslipidaemia | 3.2 | Cardiovascular disease | 4 | Hypersensitivity reaction | 5 | Toxicity, predominantly from abdomen/G-I tract | 5.1 | Toxicity - GI tract | 5.2 | Toxicity - Liver | 5.3 | Toxicity - Pancreas | 6 | Toxicity, predominantly from nervous system | 6.1 | Toxicity - peripheral neuropathy | 6.2 | Toxicity - neuropsychiatric | 6.3 | Toxicity - headache | 7 | Toxicity, predominantly from kidneys | 8 | Toxicity, predominantly from endocrine system | 8.1 | Diabetes | 9 | Haematological toxicity (anemia, etc.) | 10 | Hyperlactataemia/lactic acidosis | 11 | Bone toxicity | 15 | Social contra-indication | 16 | Contra-indication unspecified | 16.8 | Contra-indication expired | 16.9 | Contra-indication - other | 17 | MTCT regimen completed | 70 | Pregnancy - toxicity concerns (during pregnancy) | 75 | Pregnancy - switch to a more appropriate regimen for PMTCT | 88 | Death | 90 | Side effect - any of the above not mentioned | 90.1 | Comorbidity | 91 | Toxicity - other (not mentioned above) | 91.1 | Toxicity - unspecified | 92 | More effective treatment available | 92.1 | Simplified treatment available | 92.2 | Treatment too complex | 92.3 | Drug interaction | 92.31 | Drug interaction - commencing TB/BCG treatment | 92.32 | Drug interaction - ended TB/BCG treatment | 92.33 | Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) | 92.4 | Protocol change | 92.5 | Regular treatment termination (used in tblMED e.g. for DAAs against HCV, antibiotics) | 92.6 | End of empiric therapy | 92.9 | Change in treatment not due to side-effects, failure, poor adherence or contra-indication | 92.91 | Change to a generic drug | 92.92 | Change to branded drug | 93 | Structured Treatment Interruption (STI) | 93.1 | Structured Treatment Interruption (STI)-at high CD4 | 94 | Patient's wish/ decision, not specified above | 94.1 | Non-compliance | 94.2 | Defaulter | 95 | Physician's decision, not specified above | 96 | Pregnancy | 96.1 | Pregnancy intended | 96.2 | Pregnancy ended | 97 | Study treatment | 97.1 | Study treatment commenced | 97.2 | Study treatment completed | 97.6 | Drug not available | 98 | Other causes, not specified above | 99 | Unknown |
| Additional reason for stopping treatment Uses same list of codes as ART_RS |
ART_RS4 | Character See Code ListART_RS4 Code | Definition | 1 | Treatment failure (i.e. virological, immunological, and /or clinical failure) | 1.1 | Virological failure | 1.2 | Partial virological failure | 1.3 | Immunological failure - CD4 drop | 1.4 | Clinical progression | 1.5 | Resistance (based on test result) | 2 | Abnormal fat redistribution | 3 | Concern of cardiovascular disease | 3.1 | Dyslipidaemia | 3.2 | Cardiovascular disease | 4 | Hypersensitivity reaction | 5 | Toxicity, predominantly from abdomen/G-I tract | 5.1 | Toxicity - GI tract | 5.2 | Toxicity - Liver | 5.3 | Toxicity - Pancreas | 6 | Toxicity, predominantly from nervous system | 6.1 | Toxicity - peripheral neuropathy | 6.2 | Toxicity - neuropsychiatric | 6.3 | Toxicity - headache | 7 | Toxicity, predominantly from kidneys | 8 | Toxicity, predominantly from endocrine system | 8.1 | Diabetes | 9 | Haematological toxicity (anemia, etc.) | 10 | Hyperlactataemia/lactic acidosis | 11 | Bone toxicity | 15 | Social contra-indication | 16 | Contra-indication unspecified | 16.8 | Contra-indication expired | 16.9 | Contra-indication - other | 17 | MTCT regimen completed | 70 | Pregnancy - toxicity concerns (during pregnancy) | 75 | Pregnancy - switch to a more appropriate regimen for PMTCT | 88 | Death | 90 | Side effect - any of the above not mentioned | 90.1 | Comorbidity | 91 | Toxicity - other (not mentioned above) | 91.1 | Toxicity - unspecified | 92 | More effective treatment available | 92.1 | Simplified treatment available | 92.2 | Treatment too complex | 92.3 | Drug interaction | 92.31 | Drug interaction - commencing TB/BCG treatment | 92.32 | Drug interaction - ended TB/BCG treatment | 92.33 | Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) | 92.4 | Protocol change | 92.5 | Regular treatment termination (used in tblMED e.g. for DAAs against HCV, antibiotics) | 92.6 | End of empiric therapy | 92.9 | Change in treatment not due to side-effects, failure, poor adherence or contra-indication | 92.91 | Change to a generic drug | 92.92 | Change to branded drug | 93 | Structured Treatment Interruption (STI) | 93.1 | Structured Treatment Interruption (STI)-at high CD4 | 94 | Patient's wish/ decision, not specified above | 94.1 | Non-compliance | 94.2 | Defaulter | 95 | Physician's decision, not specified above | 96 | Pregnancy | 96.1 | Pregnancy intended | 96.2 | Pregnancy ended | 97 | Study treatment | 97.1 | Study treatment commenced | 97.2 | Study treatment completed | 97.6 | Drug not available | 98 | Other causes, not specified above | 99 | Unknown |
| Additional reason for stopping treatment Uses same list of codes as ART_RS |
ART_FORM | Numeric 1 = Tablet/capsule 2 = Syrup/suspension 3 = Combination of 1 and 2 4 = Powder 5 = Subcutaneous 6 = Intravenous 7 = Intramuscular 9 = Unknown
| What formulation of the drug was given? |
ART_COMB | Numeric 0 = Individual drug 1 = Part of a fixed-dose combination 9 = Unknown
| Was the drug given as part of a fixed-dose combination? |
ARTSTART_RS | Character 1 = PMTCT 30 = ARV as treatment 40 = PEP, Post Exposure Prophylaxis 50 = PREP 95 = Not ascertained 99 = Unknown despite attempting ascertainment
| Reason for starting/receiving ART |